dc.contributor.author | Au, L | |
dc.contributor.author | Fendler, A | |
dc.contributor.author | Shepherd, STC | |
dc.contributor.author | Rzeniewicz, K | |
dc.contributor.author | Cerrone, M | |
dc.contributor.author | Byrne, F | |
dc.contributor.author | Carlyle, E | |
dc.contributor.author | Edmonds, K | |
dc.contributor.author | Del Rosario, L | |
dc.contributor.author | Shon, J | |
dc.contributor.author | Haynes, WA | |
dc.contributor.author | Ward, B | |
dc.contributor.author | Shum, B | |
dc.contributor.author | Gordon, W | |
dc.contributor.author | Gerard, CL | |
dc.contributor.author | Xie, W | |
dc.contributor.author | Joharatnam-Hogan, N | |
dc.contributor.author | Young, K | |
dc.contributor.author | Pickering, L | |
dc.contributor.author | Furness, AJS | |
dc.contributor.author | Larkin, J | |
dc.contributor.author | Harvey, R | |
dc.contributor.author | Kassiotis, G | |
dc.contributor.author | Gandhi, S | |
dc.contributor.author | Crick COVID-19 Consortium, | |
dc.contributor.author | Swanton, C | |
dc.contributor.author | Fribbens, C | |
dc.contributor.author | Wilkinson, KA | |
dc.contributor.author | Wilkinson, RJ | |
dc.contributor.author | Lau, DK | |
dc.contributor.author | Banerjee, S | |
dc.contributor.author | Starling, N | |
dc.contributor.author | Chau, I | |
dc.contributor.author | CAPTURE Consortium, | |
dc.contributor.author | Turajlic, S | |
dc.date.accessioned | 2021-08-12T09:07:22Z | |
dc.date.available | 2021-08-12T09:07:22Z | |
dc.date.issued | 2021-05-26 | |
dc.identifier.citation | Nature medicine, 2021 | |
dc.identifier.issn | 1078-8956 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4743 | |
dc.identifier.eissn | 1546-170X | |
dc.identifier.doi | 10.1038/s41591-021-01387-6 | |
dc.description.abstract | Patients with cancer are currently prioritized in coronavirus disease 2019 (COVID-19) vaccination programs globally, which includes administration of mRNA vaccines. Cytokine release syndrome (CRS) has not been reported with mRNA vaccines and is an extremely rare immune-related adverse event of immune checkpoint inhibitors. We present a case of CRS that occurred 5 d after vaccination with BTN162b2 (tozinameran)-the Pfizer-BioNTech mRNA COVID-19 vaccine-in a patient with colorectal cancer on long-standing anti-PD-1 monotherapy. The CRS was evidenced by raised inflammatory markers, thrombocytopenia, elevated cytokine levels (IFN-γ/IL-2R/IL-18/IL-16/IL-10) and steroid responsiveness. The close temporal association of vaccination and diagnosis of CRS in this case suggests that CRS was a vaccine-related adverse event; with anti-PD1 blockade as a potential contributor. Overall, further prospective pharmacovigillence data are needed in patients with cancer, but the benefit-risk profile remains strongly in favor of COVID-19 vaccination in this population. | |
dc.format | Print-Electronic | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | NATURE PORTFOLIO | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Crick COVID-19 Consortium | |
dc.subject | CAPTURE Consortium | |
dc.title | Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-05-07 | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1038/s41591-021-01387-6 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2021-05-26 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Nature medicine | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/ImmNet | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/ImmNet | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.embargo.terms | Not known | |
dc.contributor.icrauthor | Shepherd, Scott | |
dc.contributor.icrauthor | Furness, Andrew | |